The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

In the BOHEMIA study, once-monthly ivermectin over 3 months significantly reduced malaria incidence versus albendazole in children aged 5 to 15 years, supporting its role as a novel vector-control ...

Rachel Smith Executive Director Rare Disease Center of Excellence Parexel International Ms. Smith brings more than a decade of experience in every development phase of rare disease and cell and gene ...